Invest in the Future of Microbiome Science
Arkaïya is at the forefront of a paradigm shift in microbiome diagnostics and probiotics. Leveraging proprietary technologies and a pioneering focus on archaea, we are disrupting markets with precision solutions for gut health and beyond.
Key Highlights
- First-Mover Advantage: Launching the world’s first M. smithii PCR test.
- Patented Technologies: Strategic IP portfolio for archaea-based probiotics and diagnostics.
- Scalable Impact: Addressing unmet needs across human and veterinary health.
- Unique Product Strengths: Leveraging M. smithii’s tolerogenic signaling and microbiome-stabilizing capacity to support immune balance, resilience, and compatibility with antibiotic treatment.
On the Horizon
Our innovative pipeline includes groundbreaking advancements in both diagnostics and next-generation probiotics, positioning us for transformative market impact in the years ahead.
Supported by FIT – Fondation pour l’Innovation et la Technologie
Arkaiya was supported through the FIT Innogrant and FIT Seed Phase to launch its diagnostic platform.
We are now introducing Switzerland’s first postal PCR kit in collaboration with an automated PCR platform at EPFL, enabling a highly scalable approach to early-life diagnostics and interventions.
Our aim is to avert immune misfirings that contribute to chronic disorders later in life.
Join us in revolutionizing gut health and advancing the science of the microbiome!
